CABOMETYX® (Cabozantinib)

The FDA on April 25, 2016 approved CABOMETYX® for the treatment of advanced Renal Cell Carcinoma, in patients who have received prior anti-angiogenic therapy. CABOMETYX® is a product of Exelixis, Inc.